Publications by authors named "A Soosaipillai"
Background: Multiple antigens, autoantibodies (AAb), and antigen-autoantibody (Ag-AAb) complexes were compared for their ability to complement CA125 for early detection of ovarian cancer.
Methods: Twenty six biomarkers were measured in a single panel of sera from women with early stage (I-II) ovarian cancers (n = 64), late stage (III-IV) ovarian cancers (186), benign pelvic masses (200) and from healthy controls (502), and then split randomly (50:50) into a training set to identify the most promising classifier and a validation set to compare its performance to CA125 alone.
Results: Eight biomarkers detected ≥ 8% of early stage cases at 98% specificity.
Article Synopsis
- - B cells play a crucial role in the immune response against tumors, particularly in melanoma, but their specific functions and characteristics have not been fully explored until now.
- - In this study, researchers found that memory B cells are more prevalent in tumors than in the bloodstream and exhibit unique antibody profiles that indicate processes like clonal expansion and affinity maturation.
- - The presence of tumor-associated B cells with autoimmune-like traits and high levels of antibodies related to both autoimmune diseases and cancer suggests a dysregulated immune response in melanoma patients.
Background: Gliomas are among the most malignant tumors, with a very poor prognosis. Early diagnosis is highly desirable since it can help implement more effective treatments for smaller tumors, which have not yet extensively metastasized. Improving early diagnosis may facilitate access of patients to clinical trials and prepare them for the future availability of new disease-modifying treatments.
View Article and Find Full Text PDFObjectives: Ovarian cancer is the most lethal gynecological malignancy in developed countries. One of the key associations with the high mortality rate is diagnosis at late stages. This clinical limitation is primarily due to a lack of distinct symptoms and detection at the early stages.
View Article and Find Full Text PDFObjectives: Immune checkpoint inhibitors (ICIs) cause a variety of toxicities, including immune-related adverse events (irAEs), but there are no biomarkers to predict their development. Guidelines recommend measuring circulating cardiac troponin I (cTnI) during ICI therapy to detect related cardiotoxicities. Moreover, elevated cTnI has also been associated with worse outcomes in non-cardiac patients, including cancer.
View Article and Find Full Text PDF